Assessing the Clinical Benefit of Systemic Adjuvant Therapies for Early Breast Cancer.

about

Assessing the Clinical Benefit of Systemic Adjuvant Therapies for Early Breast Cancer.

Item

http://www.wikidata.org/entity/Q47138534

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Assessing the Clinical Benefit of Systemic Adjuvant Therapies for Early Breast Cancer.

@en

Assessing the Clinical Benefit of Systemic Adjuvant Therapies for Early Breast Cancer.

@nl

type

Item

label

Assessing the Clinical Benefit of Systemic Adjuvant Therapies for Early Breast Cancer.

@en

Assessing the Clinical Benefit of Systemic Adjuvant Therapies for Early Breast Cancer.

@nl

prefLabel

Assessing the Clinical Benefit of Systemic Adjuvant Therapies for Early Breast Cancer.

@en

Assessing the Clinical Benefit of Systemic Adjuvant Therapies for Early Breast Cancer.

@nl

P1476

Assessing the Clinical Benefit of Systemic Adjuvant Therapies for Early Breast Cancer.

@en

P2093

Marcus Schmidt

http://www.w3.org/2001/XMLSchema#string

Susanne Hell

http://www.w3.org/2001/XMLSchema#string

Volker Möbus

http://www.w3.org/2001/XMLSchema#string

P2860

Trastuzumab containing regimens for early breast cancer

Taxanes for adjuvant treatment of early breast cancer

Preoperative chemotherapy for women with operable breast cancer

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

Adjuvant Dose-Dense Chemotherapy in Breast Cancer: Standard of Care in High-Risk Patients

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

Adjuvant chemotherapy, with or without taxanes, in early or operable breast cancer: a meta-analysis of 19 randomized trials with 30698 patients

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

P304

1079-1087

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1055/S-0043-119542

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29093601

http://www.w3.org/2001/XMLSchema#string

P932

5658231

http://www.w3.org/2001/XMLSchema#string